At the Center for BRCA Research, we pursue laboratory, clinical, and population research. Our research is centered around patients and their families, to help improve patient outcomes and create a better model of care.
Please contact us at [email protected] if you are interested in participating in any of our research studies.
Below are the research studies currently taking place:
Prevention: BRCA-P
The purpose of this study is to determine the preventative effect of Denosumab on breast cancer in women carrying a BRCA1 pathogenic variant.
Early Detection: Pancreatic Cancer Screening
The purpose of this study is to determine the frequency of abnormal MRI findings in BRCA, ATM, and PALB2 pathogenic variant carriers for those with and without a strong family history of pancreatic cancer. This study is also exploring early signs of pancreatic cancer and investigating biopsy and surgery procedures.
Biomarker: PRECiSE
The purpose of this study is to assess the predictive capabilities of cell-free DNA as a screening tool for ovarian cancer. With improved screening methods for ovarian cancer, we hope to catch ovarian cancer at earlier stages and improve survival rate.
Descriptive: eGene
eGene is a tech-integrated, large scale, long term and in-depth study on lifestyle and how they affect health outcomes and cancer risk. In this study, the researchers are asking participants to complete a questionnaire so that we may learn if certain behaviors, where you live, your medical history, or how much you exercise are linked to an increase in cancer risk.
Biorepository: Center for BRCA Research Biorepository
The purpose of this study is to collect blood, tissue, saliva, or other samples (such as hair, urine, stool, etc.) from patients with a known genetic pathogenic variant, or who have a strong family history of cancer and do not know if they have a genetic pathogenic variant. These samples and information from your medical record will be safely stored (banked) for use in future studies looking at genetic pathogenic variants, and other factors, that might be related to the growth and treatment of cancer.
Therapeutic:
The goal of these therapeutic studies is to determine if the new drugs are safe, effective at slowing or stopping cancer growth, and potentially better to existing treatments.
Olaparib and ASTX727 trial (NCT23992): This study is testing a combination of two drugs, olaparib and ASTX727, in adults with advanced cancers that have spread in the body. The study focuses on people with pathogenic variants BRCA1, BRCA2, PALB2, ATM, and CHEK2.
Eikon trial (NCT06253130): This study is looking at a new drug called IMP1734 for patients with advanced breast, ovarian, or prostate cancer. The study focuses on people with pathogenic variants BRCA1, BRCA2, PALB2, RAD51B, RAD51C, RAD51D.
Niraparib trial (NCT05694715): This study is combining two drugs: niraparib, which targets cancer cells with certain genetic weaknesses, and irinotecan, a type of chemotherapy. The study focuses on people whose cancer has spread and who have pathogenic variants BRCA1/2, ATM, or PALB2. The researchers are particularly interested in cancers of the digestive system, ovaries, and breast.
GSK POLQi Study (CC#219590): This is an early-stage study testing a new oral medication called GSK4524101, which blocks a protein called DNA Polymerase Theta. The study will also test this drug in combination with another medication called niraparib. The study focuses on adult patients with solid tumors (cancers).
MOMA Study (CC#249516): This study is testing a new drug called MOMA-313, alone and also combined with another cancer drug called a PARP inhibitor. The study focuses on people who have advanced solid tumors that have spread in their body.
POLAR Trial (CC#PENDING): This is an early-stage study of a new drug called RP-3467, alone and also with another cancer drug called olaparib. The study focuses on people with advanced solid tumors.